Working to Eradicate Gynecologic Cancers

Kathleen M. Darcy, PhD

Chief Operations Officer
Gynecologic Cancer Center of Excellence
3289 Woodburn Rd
Suite 370
Annandale, VA
USA 22003

Papers:
43 - Featured Poster Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes 49 - Featured Poster Pathogenesis of ARID1A-driven gynecologic cancer 98 - Featured Poster Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence 282 - Poster Session A Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly 295 - Poster Session A Curated Ovarian Database-derived identification of genes predicting survival in primary serous epithelial ovarian cancer 306 - Poster Session A Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells 337 - Poster Session A Proteomics of endometrial carcinogenesis: identification of candidates underlying disease pathogenesis 525 - Poster Session B Correlation of survival-stratified proteomic and curated gene data reveal a three protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer 526 - Poster Session B Diminished survival of separated, divorced, or widowed uterine cancer patients: a potential focus for survivorship programs